Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: kech who wrote (127)	3/29/1998 10:34:00 PM
From: Shlepper	Read Replies (1) \| Respond to of 233

Tom, I'll try to get through tomorrow or Tuesday to get the scoop. My gut feeling is that they have all of the data that they need (but maybe not all is machine readable), but need to go back to retrieve (from source documents, etc.) and analyze additional data. I don't think they need to conduct additional tests. If they did, unless it were minimal procedures, would mean more than the 6 month delay they've indicated. My company works with pharmas in their clinical trials (among many other fields such as transportation and education). The process is quite complex, and the FDA is pretty touchy about their guidelines and standards. I suppose Magainin has enlisted those who know the ropes to get this through. Companies like Guilford hired people from the FDA to gain the expertise on how to get through the process. Sounds like a wise investment - at least it worked for Guilford. I think the entire market will be tanking this next month, but biotechs - with FDA approval and potential may become the darlings - as the overvalued blue chips take the hit. Good Luck, Shep